Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 1449

1.

[Use of herbal medicine for cancer treatment-related toxicities].

Samuels N, Morag O, Maimon Y.

Harefuah. 2015 Jan;154(1):43-6, 67. Hebrew.

PMID:
25796675
2.

Functional TP53 mutations have no impact on response to cytotoxic agents in metastatic colon cancer.

Netter J, Lehmann-Che J, Lambert J, Tallet A, Lourenco N, Soliman H, Bertheau P, Pariente B, Chirica M, Pocard M, Allez M, De The H, Gornet JM.

Bull Cancer. 2015 Feb;102(2):117-25. doi: 10.1016/j.bulcan.2014.12.010. Epub 2015 Jan 20.

3.

[Systemic chemotherapy and surgery for recurrent metachronous liver metastases with peritoneal dissemination from triple colon cancers-a case report].

Kato T, Noda H, Watanabe F, Kakizawa N, Toyama N, Rikiyama T.

Gan To Kagaku Ryoho. 2014 Dec;41(13):2615-7. Japanese.

PMID:
25596059
4.

[Blindness and symmetrical neurological deficit in a patient with colon cancer receiving adjuvant chemotherapy: is it always cancer?].

Leshem Y, Fennig S, Talianski E, Greenberg G, Wolf I.

Harefuah. 2014 Nov;153(11):650-1, 687. Hebrew.

PMID:
25563024
5.

[Immediate and late follow-up results of surgical and combined treatment of patients with colonic cancer of various localization in right half of the colon].

Miasoedov SD, Koshel' KV, Miasoedov DV, Gordiń≠chuk PI, Tersenov IaA, Kukhar IV, Bogdanova SI.

Klin Khir. 2014 Sep;(9):14-8. Russian.

PMID:
25509426
6.

Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controlled trials.

Schmoll HJ, Twelves C, Sun W, O'Connell MJ, Cartwright T, McKenna E, Saif M, Lee S, Yothers G, Haller D.

Lancet Oncol. 2014 Dec;15(13):1481-92. doi: 10.1016/S1470-2045(14)70486-3. Epub 2014 Nov 12.

PMID:
25456367
7.

[A case of mFOLFOX6-induced lactic acidosis in a patient with colon cancer].

Ito A, Kawamoto K, Park T, Ito T.

Gan To Kagaku Ryoho. 2014 Nov;41(11):1445-7. Japanese.

PMID:
25434453
8.

Aspirin and COX-2 inhibitor use in patients with stage III colon cancer.

Ng K, Meyerhardt JA, Chan AT, Sato K, Chan JA, Niedzwiecki D, Saltz LB, Mayer RJ, Benson AB 3rd, Schaefer PL, Whittom R, Hantel A, Goldberg RM, Venook AP, Ogino S, Giovannucci EL, Fuchs CS.

J Natl Cancer Inst. 2014 Nov 27;107(1):345. doi: 10.1093/jnci/dju345. Print 2015 Jan.

PMID:
25432409
9.

DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147).

Lee AM, Shi Q, Pavey E, Alberts SR, Sargent DJ, Sinicrope FA, Berenberg JL, Goldberg RM, Diasio RB.

J Natl Cancer Inst. 2014 Nov 7;106(12). pii: dju298. doi: 10.1093/jnci/dju298. Print 2014 Dec.

PMID:
25381393
10.

Adjuvant chemotherapy for t1 node-positive colon cancers provides significant survival benefit.

Ganapathi AM, Speicher PJ, Englum BR, Castleberry AW, Migaly J, Hsu DS, Mantyh CR.

Dis Colon Rectum. 2014 Dec;57(12):1341-8. doi: 10.1097/DCR.0000000000000245.

11.

Functional and morphological effects of systemic bevacizumab on cancer patients' eyes.

Yildiz BK, Ozdek S, Demirci U, Ceylanoglu KS, Ozmen MC, Baykara M, Buyukberber S, Coskun U, Benekli M.

Optom Vis Sci. 2015 Jan;92(1):102-6. doi: 10.1097/OPX.0000000000000430.

PMID:
25360703
13.

Adjuvant chemotherapy use and outcomes of patients with high-risk versus low-risk stage II colon cancer.

Kumar A, Kennecke HF, Renouf DJ, Lim HJ, Gill S, Woods R, Speers C, Cheung WY.

Cancer. 2015 Feb 15;121(4):527-34. doi: 10.1002/cncr.29072. Epub 2014 Oct 20.

PMID:
25332117
14.

Provider-based research networks may improve early access to innovative colon cancer treatment for African Americans treated in the community.

Penn DC, Chang Y, Meyer AM, DeFilippo Mack C, Sanoff HK, Stitzenberg KB, Carpenter WR.

Cancer. 2015 Jan 1;121(1):93-101. doi: 10.1002/cncr.29028. Epub 2014 Sep 10.

PMID:
25209056
15.

Hoarseness after metastatic colon cancer treatment.

Caruso AM, Meyer TK, Allen CT.

JAMA Otolaryngol Head Neck Surg. 2014 Sep;140(9):881-2. doi: 10.1001/jamaoto.2014.1766. No abstract available.

PMID:
25144305
16.

[A case of disseminated carcinomatosis of the bone marrow with disseminated intravascular coagulation caused by advanced colon cancer successfully treated with SOX/bevacizumab].

Suzuki H, Matsuoka N, Ushimaru Y, Kakimoto Y, Toyoda A, Endo Y, Murakami O, Kato Y, Inoue M, Kimura T, Matsuda Y, Sasakabe H.

Gan To Kagaku Ryoho. 2014 Aug;41(8):1013-6. Review. Japanese.

PMID:
25132036
17.

[Successful treatment of advanced sigmoid colon cancer with liver metastases with cetuximab monotherapy as first-line treatment-a case report].

Harada K, Hatanaka K, Kinoshita K, Kawamoto Y, Yamato H, Ogawa K, Yamamoto Y, Naruse H.

Gan To Kagaku Ryoho. 2014 Jul;41(7):897-900. Japanese.

PMID:
25131880
18.

[A case of pathologically complete response in a patient with locally advanced sigmoid colon cancer after chemotherapy including bevacizumab/FOLFOX4].

Mikami Y, Tamura N, Akiyama M, Muraoka T, Sakurai U, Sawabe M.

Gan To Kagaku Ryoho. 2014 Jun;41(6):777-9. Japanese.

PMID:
25129094
19.

Risk factors for the requirement of surgical or endoscopic interventions during chemotherapy in patients with uncomplicated colorectal cancer and unresectable synchronous metastases.

Yun JA, Park Y, Huh JW, Cho YB, Yun SH, Kim HC, Lee WY, Chun HK.

J Surg Oncol. 2014 Dec;110(7):839-44. doi: 10.1002/jso.23725. Epub 2014 Jul 18.

PMID:
25043872
20.

Phase Ib study of dovitinib in combination with gemcitabine plus cisplatin or gemcitabine plus carboplatin in patients with advanced solid tumors.

Galsky MD, Posner M, Holcombe RF, Lee KM, Misiukiewicz K, Tsao CK, Godbold J, Soto R, Gimpel-Tetra K, Lowe N, Oh WK.

Cancer Chemother Pharmacol. 2014 Sep;74(3):465-71. doi: 10.1007/s00280-014-2518-5. Epub 2014 Jul 15.

PMID:
25023489
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk